Pfizer CEO Albert Bourla details $70B US investment in manufacturing and R&D, discussing oncology advancements, the GLP-1 drug race, and AI's transformative role in drug development on 'Mornings with Maria.'
Pfizer's strategic $70 billion investment in U.S. manufacturing and research & development aims to bolster domestic pharmaceutical innovation. CEO Albert Bourla outlines progress in oncology, the company's aggressive entry into the GLP-1 market. He highlights AI's transformative potential in accelerating drug discovery and expresses confidence in reducing healthcare costs.
